Teva's TEV-'749 shows improved social functioning in schizophrenia patients in Phase 3 SOLARIS trial.
Read more
Exactech's Truliant 3D Tibial Implant receives FDA clearance for knee replacement surgery.
Read more
FELIQS' FLQ-101 receives FDA Fast Track for Retinopathy of Prematurity prevention.
Read more
Hypothyroidism market to grow by USD 789.8 million by 2028, driven by new drug approvals and AI advancements.
Read more
Cancer drugs Palbociclib and Ribociclib show potential in treating Hereditary Hemorrhagic Telangiectasia by targeting CDK6 protein.
Read more
Kewaunee Scientific acquires Nu Aire for $55 million, expanding laboratory furniture and technical product offerings.
Read more
Galecto acquires rights to BRM-1420 for Acute Myeloid Leukemia, focusing on oncology and liver diseases.
Read more
Aileron and Advancium sign exclusive option agreement for ALRN-6924 to treat Retinoblastoma.
Read more
Evogene partners with Google Cloud to enhance AI-driven small molecule design for drug development and agriculture.
Read more
FDA approves Novartis' Scemblix for newly diagnosed Chronic Myeloid Leukemia, showing superior efficacy and safety in Phase III trial.
Read more
Anavex's Blarcamesine shows significant efficacy in Phase IIb/III trial for Alzheimer's Disease, slowing clinical decline by 36.3%.
Read more
Verastem submits NDA for avutometinib and defactinib to FDA for recurrent KRAS mutant low-grade serous ovarian cancer.
Read more
Accenture partners with 1910 Genetics to enhance drug discovery using AI for biopharma companies.
Read more
Illumina unveils new NGS and proteomics technologies at ASHG, enhancing genomic insights and multiomics capabilities.
Read more
Eisai completes FDA submission for LEQEMBI subcutaneous dosing for early Alzheimer's Disease under Fast Track status.
Read more
Seer showcases deep proteomics enhancing genomic insights for Alzheimer's Disease and Lung Cancer at ASHG 2024.
Read more
Sutro Biopharma initiates trial for Luvelta in pediatric patients with CBF/GLIS Acute Myeloid Leukemia.
Read more
Genentech's Itovebi doubles progression-free survival in HR-positive advanced Breast Cancer, per NEJM Phase III study.
Read more
Memo Therapeutics completes Phase II trial enrollment for potravitug in BK Viremia among kidney transplant patients.
Read more
ALX Oncology's evorpacept shows promise in Phase 1b/2 trial for HER2-positive metastatic breast cancer.
Read more
Blue Earth Therapeutics secures $76.5M to advance PSMA-targeted radioligand therapies for Prostate Cancer.
Read more
Biogen and Neomorph partner to develop molecular glue degraders for Alzheimer's Disease and rare immunological conditions.
Read more
Corcept reports positive Phase 3 trial results for relacorilant in Cushing's Syndrome, boosting financial outlook.
Read more
Diadem's p53-specific antibody shows promise for early Alzheimer's Disease detection at CTAD 2024.
Read more
Senhwa Biosciences appoints Dr. Yiu-Lian Fong as Corporate Director to enhance oncology and rare disease drug development.
Read more
